ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre
ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre
复制标题
DOI：
10.1183/09031936.00078411
复制
发表时间：
2012-04-01
影响因子：
24.3
通讯作者：
Kiely, D. G.
中科院分区：
文献类型：
--
作者：
Hurdman, J.;Condliffe, R.;Kiely, D. G.
肺动脉高压（PH）是一种异质性疾病。到目前为止，没有登记数据存在反映疾病谱在五个诊断组遇到的专家referrerationcenter.Data检索连续，治疗初治病例诊断之间的2001年和2010年使用基于导管的方法。共纳入1,344例患者，平均随访2.9年。肺动脉高压（PAH）的3年生存率为68%，PH伴左心疾病的3年生存率为73%，PH伴肺部疾病的3年生存率为44%，慢性血栓栓塞性PH（CTEPH）的3年生存率为71%，其他PH的3年生存率为59%。与PAH相比，PH肺的生存率较低，CTEPH的生存率上级（p
Pulmonary hypertension (PH) is a heterogeneous condition. To date, no registry data exists reflecting the spectrum of disease across the five diagnostic groups encountered in a specialist referral centre.Data was retrieved for consecutive, treatment-naive cases diagnosed between 2001 and 2010 using a catheter-based approach. 1,344 patients were enrolled, with a mean follow-up of 2.9 yrs.The 3-yr survival was 68% for pulmonary arterial hypertension (PAH), 73% for PH associated with left heart disease, 44% for PH associated with lung disease (PH-lung), 71% for chronic thromboembolic PH (CTEPH) and 59% for miscellaneous PH. Compared with PAH, survival was inferior in PH-lung and superior in CTEPH (p